Inactive Instrument

News Anthera Pharmaceuticals Inc Nasdaq

Equities

US03674U3005

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from S&P TMI Index	18-07-02	CI
Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from NASDAQ Composite Index	18-06-27	CI
Anthera Pharmaceuticals, Inc. Reports Top Line Data from the Result Phase 3 Clinical Study of Sollpura	18-03-12	CI
Transcript : Anthera Pharmaceuticals, Inc. - Special Call	18-03-12
Anthera Mulls Acquisitions	18-03-06	CI
Anthera Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017	18-03-05	CI
Anthera Pharmaceuticals, Inc. Concludes Last Patient Visit in the Phase 3 Result Clinical Study of Sollpura	18-02-05	CI
Anthera Pharmaceuticals, Inc. announced that it has received $15 million in funding from a group of investors	18-01-08	CI
Anthera Pharmaceuticals, Inc. Appoints Patrick Murphy as Senior Vice President, Manufacturing	18-01-03	CI
Anthera Pharmaceuticals, Inc. Announces Positive Outcome of Interim Futility Analysis in the Phase 3 Result Clinical Study of Sollpura	17-12-11	CI
Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura	17-11-09	CI
Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	17-11-06	CI
Anthera Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from a group of investors	17-10-22	CI
Anthera Pharmaceuticals, Inc. Announces Top Line Final Data from Phase 2 BRIGHT-SC Study of Blisibimod	17-08-28	CI
Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017	17-08-09	CI
Anthera Pharmaceuticals, Inc. Announces Executive Changes	17-07-14	CI
Anthera Pharmaceuticals, Inc. Announces Commencement of Screening in European Sites in Phase 3 Result Clinical Study of Sollpura	17-07-06	CI
Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) dropped from Russell 3000 Index	17-06-23	CI
Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) dropped from Russell 2000 Index	17-06-23	CI
Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from Russell 2000 Dynamic Index	17-06-23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Anthera Pharmaceuticals Inc Nasdaq

Equities

US03674U3005

Summary

Filters